{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:00:37Z","timestamp":1781794837244,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s11910-022-01205-7","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T06:07:45Z","timestamp":1654322865000},"page":"355-362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Neurological Manifestations of Acute Porphyrias"],"prefix":"10.1007","volume":"22","author":[{"given":"Kyle","family":"Wylie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando D.","family":"Testai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,4]]},"reference":[{"key":"1205_CR1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ymgme.2018.11.012","volume":"128","author":"M Yasuda","year":"2019","unstructured":"Yasuda M, Chen B, Desnick RJ. Recent advances on porphyria genetics: inheritance, penetrance & molecular heterogeneity, including new modifying\/causative genes. Mol Genet Metab. 2019;128:320\u201331.","journal-title":"Mol Genet Metab"},{"key":"1205_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(09)61925-5","volume":"375","author":"H Puy","year":"2010","unstructured":"Puy H, Gouya L, Deybach J. Porphyrias. Lancet. 2010;375:924\u201337.","journal-title":"Lancet"},{"key":"1205_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.17219\/acem\/58955","volume":"25","author":"U Szlendak","year":"2016","unstructured":"Szlendak U, Bykowska K, Lipniacka A. Clinical, biochemical and molecular characteristics of the main types of porphyria. Adv Clin Exp Med. 2016;25:361\u20138.","journal-title":"Adv Clin Exp Med"},{"key":"1205_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ymgme.2019.04.008","volume":"128","author":"JD Phillips","year":"2019","unstructured":"Phillips JD. Heme biosynthesis and the porphyrias. Mol Genet Metab. 2019;128:164\u201377 (\u2022 This publication provides a detailed description of the biochemistry of heme.).","journal-title":"Mol Genet Metab"},{"key":"1205_CR5","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1007\/s00415-008-0779-9","volume":"255","author":"E Pischik","year":"2008","unstructured":"Pischik E, Kazakov V, Kauppinen R. Is screening for urinary porphobilinogen useful among patients with acute polyneuropathy or encephalopathy? J Neurol. 2008;255:974\u20139.","journal-title":"J Neurol"},{"key":"1205_CR6","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1080\/00207454.2019.1655014","volume":"129","author":"Y Suh","year":"2019","unstructured":"Suh Y, Gandhi J, Seyam O, Jiang W, Joshi G, Smith NL, Ali KS. Neurological and neuropsychiatric manifestations of porphyria. Int J Neurosci. 2019;129:1226\u201333.","journal-title":"Int J Neurosci"},{"key":"1205_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ebcr.2016.08.004","volume":"6","author":"DC Silveira","year":"2016","unstructured":"Silveira DC, Bashir M, Daniel J, Lucena MH, Bonpietro F. Acute intermittent porphyria presenting with posterior reversible encephalopathy syndrome and lateralized periodic discharges plus fast activity on EEG. Epilepsy Behav Case Rep. 2016;6:58\u201360.","journal-title":"Epilepsy Behav Case Rep"},{"key":"1205_CR8","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2169\/internalmedicine.56.7654","volume":"56","author":"T Takata","year":"2017","unstructured":"Takata T, Kume K, Kokudo Y, Ikeda K, Kamada M, Touge T, Deguchi K, Masaki T. Acute intermittent porphyria presenting with posterior reversible encephalopathy syndrome, accompanied by prolonged vasoconstriction. Intern Med. 2017;56:713\u20137.","journal-title":"Intern Med"},{"key":"1205_CR9","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3389\/fneur.2020.00463","volume":"11","author":"R Anderson","year":"2020","unstructured":"Anderson R, Patel V, Sheikh-Bahaei N, Liu CSJ, Rajamohan AG, Shiroishi MS, Kim PE, Go JL, Lerner A, Acharya J. Posterior reversible encephalopathy syndrome (PRES): pathophysiology and neuro-imaging. Front Neurol. 2020;11:463.","journal-title":"Front Neurol"},{"key":"1205_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011665","volume":"97","author":"X Zheng","year":"2018","unstructured":"Zheng X, Liu X, Wang Y, Zhao R, Qu L, Pei H, Tuo M, Zhang Y, Song Y, Ji X, et al. Acute intermittent porphyria presenting with seizures and posterior reversible encephalopathy syndrome: two case reports and a literature review. Medicine (Baltimore). 2018;97: e11665.","journal-title":"Medicine (Baltimore)"},{"key":"1205_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.pediatrneurol.2014.05.016","volume":"51","author":"B Zhao","year":"2014","unstructured":"Zhao B, Wei Q, Wang Y, Chen Y, Shang H. Posterior reversible encephalopathy syndrome in acute intermittent porphyria. Pediatr Neurol. 2014;51:457\u201360.","journal-title":"Pediatr Neurol"},{"key":"1205_CR12","doi-asserted-by":"crossref","unstructured":"Rasheed F, Mehdi QS, Bhatti S, Khan MMA. Posterior reversible encephalopathy syndrome in a patient with variegate porphyria: a case report. Cureus . 2018;10.","DOI":"10.7759\/cureus.3351"},{"key":"1205_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/sj.jhh.1001664","volume":"18","author":"G Hagemann","year":"2004","unstructured":"Hagemann G, Ugur T, Witte OW, Fitzek C. Recurrent posterior reversible encephalopathy syndrome (PRES). J Hum Hypertens. 2004;18:287\u20139.","journal-title":"J Hum Hypertens"},{"key":"1205_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fneur.2020.00034","volume":"11","author":"F Pilato","year":"2020","unstructured":"Pilato F, Distefano M, Calandrelli R. Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome: clinical and radiological considerations. Front Neurol. 2020;11:34.","journal-title":"Front Neurol"},{"key":"1205_CR15","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/practneurol-2012-000288","volume":"12","author":"S Mullin","year":"2012","unstructured":"Mullin S, Platts A, Randhawa K, Watts P. Cerebral vasospasm and anterior circulation stroke secondary to an exacerbation of hereditary corproporphyria. Pract Neurol. 2012;12:384\u20137.","journal-title":"Pract Neurol"},{"key":"1205_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s12028-018-0548-2","volume":"29","author":"L Bastide","year":"2018","unstructured":"Bastide L, Legros B, Rampal N, Gilmore EJ, Hirsch LJ, Gaspard N. Clinical correlates of periodic discharges and nonconvulsive seizures in posterior reversible encephalopathy syndrome (PRES). Neurocrit Care. 2018;29:481\u201390.","journal-title":"Neurocrit Care"},{"key":"1205_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ebcr.2018.11.002","volume":"11","author":"S Dawit","year":"2019","unstructured":"Dawit S, Bhatt SK, Das DM, Pines AR, Shiue HJ, Goodman BP, Drazkowski JF, Sirven JI. Nonconvulsive status epilepticus secondary to acute porphyria crisis. Epilepsy Behav Case Rep. 2019;11:43\u20136.","journal-title":"Epilepsy Behav Case Rep"},{"key":"1205_CR18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000353279","volume":"5","author":"TPY Tran","year":"2013","unstructured":"Tran TPY, Leduc K, Savard M, Dupr\u00e9 N, Rivest D, Nguyen DK. Acute porphyria presenting as epilepsia partialis continua. Case Rep Neurol. 2013;5:116\u201324.","journal-title":"Case Rep Neurol"},{"key":"1205_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ymgme.2019.03.002","volume":"128","author":"HL Bonkovsky","year":"2019","unstructured":"Bonkovsky HL, Dixon N, Rudnick S. Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs). Mol Genet Metab. 2019;128:213\u20138.","journal-title":"Mol Genet Metab"},{"key":"1205_CR20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ymgme.2019.10.011","volume":"128","author":"DA Jaramillo-Calle","year":"2019","unstructured":"Jaramillo-Calle DA, Solano JM, Rabinstein AA, Bonkovsky HL. Porphyria-induced posterior reversible encephalopathy syndrome and central nervous system dysfunction. Mol Genet Metab. 2019;128:242\u201353.","journal-title":"Mol Genet Metab"},{"key":"1205_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/B978-0-7020-4086-3.00012-6","volume":"119","author":"RS Price","year":"2014","unstructured":"Price RS, Kasner SE. Hypertension and hypertensive encephalopathy. Handb Clin Neurol. 2014;119:161\u20137.","journal-title":"Handb Clin Neurol"},{"key":"1205_CR22","first-page":"32","volume":"11","author":"M Alqwaifly","year":"2019","unstructured":"Alqwaifly M, Bril V, Dodig D. Acute intermittent porphyria: a report of 3 cases with neuropathy. CRN. 2019;11:32\u20136.","journal-title":"CRN"},{"key":"1205_CR23","first-page":"311","volume":"56","author":"B Mutluay","year":"2019","unstructured":"Mutluay B, K\u00f6ksal A, \u00c7el\u0131k RGG, B\u00fclb\u00fcl HH. A case of acute intermittent porphyria mimicking Guillain-Barr\u00e9 syndrome. Noro Psikiyatr Ars. 2019;56:311\u20132.","journal-title":"Noro Psikiyatr Ars"},{"key":"1205_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.17925\/USN.2020.16.1.66","volume":"16","author":"N Rad","year":"2020","unstructured":"Rad N, Beydoun SR. Porphyria-induced recurrent quadriplegia misdiagnosed as Guillain-Barr\u00e9 syndrome. US Neurol. 2020;16:66.","journal-title":"US Neurol"},{"key":"1205_CR25","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/mus.23367","volume":"46","author":"G Barraza","year":"2012","unstructured":"Barraza G, Serranova T, Herrero C, Casanova-Moll\u00e1 J, To-Figueras J, Herranz J, Valls-Sol\u00e9 J. Brainstem dysfunction in variegate porphyria. Muscle Nerve. 2012;46:426\u201333.","journal-title":"Muscle Nerve"},{"key":"1205_CR26","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.2147\/TCRM.S180161","volume":"15","author":"Z Spiritos","year":"2019","unstructured":"Spiritos Z, Salvador S, Mosquera D, Wilder J. Acute intermittent porphyria: current perspectives and case presentation. TCRM. 2019;15:1443\u201351.","journal-title":"TCRM"},{"key":"1205_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3126\/kumj.v10i2.7354","volume":"10","author":"A Nabin","year":"2012","unstructured":"Nabin A, Thapa LJ, Paudel R, Rana PVS. Acute intermittent porphyria with SIADH and fluctuating dysautonomia. Kathmandu Univ Med J. 2012;10:96\u20139.","journal-title":"Kathmandu Univ Med J"},{"key":"1205_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2022.100842","volume":"30","author":"K Baumann","year":"2022","unstructured":"Baumann K, Kauppinen R. Long-term follow-up of acute porphyria in female patients: update of clinical outcome and life expectancy. Mol Genet Metab Rep. 2022;30: 100842 (\u2022\u2022 Large database of porphyria cases with long-term follow-up providing insight into frequency of complications.).","journal-title":"Mol Genet Metab Rep"},{"key":"1205_CR29","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3390\/diagnostics11122205","volume":"11","author":"A Ricci","year":"2021","unstructured":"Ricci A, Di Pierro E, Marcacci M, Ventura P. Mechanisms of neuronal damage in acute hepatic porphyrias. Diagnostics (Basel). 2021;11:2205 (\u2022 Detailed description of the pathogenic mechanisms associated with neuronal damage in porphyrias.).","journal-title":"Diagnostics (Basel)."},{"key":"1205_CR30","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0925-4439(92)90069-Y","volume":"1180","author":"M Hermes-Lima","year":"1992","unstructured":"Hermes-Lima M, Castilho RF, Valle VG, Bechara EJ, Vercesi AE. Calcium-dependent mitochondrial oxidative damage promoted by 5-aminolevulinic acid. Biochim Biophys Acta. 1992;1180:201\u20136.","journal-title":"Biochim Biophys Acta"},{"key":"1205_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0197-0186(02)00074-8","volume":"42","author":"T Emanuelli","year":"2003","unstructured":"Emanuelli T, Pagel FW, Porci\u00fancula LO, Souza DO. Effects of 5-aminolevulinic acid on the glutamatergic neurotransmission. Neurochem Int. 2003;42:115\u201321.","journal-title":"Neurochem Int"},{"key":"1205_CR32","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/ana.410020415","volume":"2","author":"WE M\u00fcller","year":"1977","unstructured":"M\u00fcller WE, Snyder SH. delta-Aminolevulinic acid: influences on synaptic GABA receptor binding may explain CNS symptoms of porphyria. Ann Neurol. 1977;2:340\u20132.","journal-title":"Ann Neurol"},{"key":"1205_CR33","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/BF00964997","volume":"8","author":"VA Russell","year":"1983","unstructured":"Russell VA, Lamm MC, Taljaard JJ. Inhibition of Na+, K+-ATPase activity by delta-aminolevulinic acid. Neurochem Res. 1983;8:1407\u201315.","journal-title":"Neurochem Res"},{"key":"1205_CR34","doi-asserted-by":"crossref","unstructured":"Lin CS-, Krishnan AV, Lee M, Zagami AS, You H, Yang C, Bostock H, Kiernan MC. Nerve function and dysfunction in acute intermittent porphyria. Brain . 2008;131:2510\u20132519.","DOI":"10.1093\/brain\/awn152"},{"key":"1205_CR35","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/347768a0","volume":"347","author":"DS Bredt","year":"1990","unstructured":"Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature. 1990;347:768\u201370.","journal-title":"Nature"},{"key":"1205_CR36","unstructured":"\u2022\u2022 The drug database for acute porphyria. Available at: http:\/\/www.drugs-porphyria.org\/. Accessed April 11, 2022. (Updated database containing safety of drugs in porphyria.)"},{"key":"1205_CR37","unstructured":"\u2022\u2022 American Porphyria Foundation Drug Database. Available at: https:\/\/porphyriafoundation.org\/drugdatabase\/. Accessed Apr 11, 2022. (Updated database containing safety of drugs in porphyria.)"},{"key":"1205_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2017.09.013","volume":"77","author":"J Vidaurre","year":"2017","unstructured":"Vidaurre J, Gedela S, Yarosz S. Antiepileptic drugs and liver disease. Pediatr Neurol. 2017;77:23\u201336.","journal-title":"Pediatr Neurol"},{"key":"1205_CR39","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40265-021-01511-3","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed YY. Givosiran: a review in acute hepatic porphyria. Drugs. 2021;81:841\u20138.","journal-title":"Drugs"},{"key":"1205_CR40","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/0004563212474555","volume":"50","author":"P Stein","year":"2013","unstructured":"Stein P, Badminton M, Barth J, Rees D, Stewart MF. Best practice guidelines on clinical management of acute attacks of porphyria and their complications. Ann Clin Biochem. 2013;50:217\u201323.","journal-title":"Ann Clin Biochem"},{"key":"1205_CR41","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1056\/NEJMra1608634","volume":"377","author":"DM Bissell","year":"2017","unstructured":"Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 2017;377:862\u201372.","journal-title":"N Engl J Med"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-022-01205-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-022-01205-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-022-01205-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T03:33:58Z","timestamp":1656473638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-022-01205-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,4]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1205"],"URL":"https:\/\/doi.org\/10.1007\/s11910-022-01205-7","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,4]]},"assertion":[{"value":"21 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kyle Wylie and Fernando D. Testai each declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}